학술논문
Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial
Document Type
Journal Article
Author
Hiroyuki Tsutsui; Ikuyo Ichi; Junji Kishimoto; Keiji Oi; Kenichi Eshima; Kenji Miyata; Kenji Sadamatsu; Kiyoshi Hironaga; Koji Todaka; Makoto Usui; Masao Takemoto; Mitsutaka Yamamoto; Nobuhiro Suematsu; Shujiro Inoue; Shunsuke Katsuki; Soichi Nakashiro; Susumu Takase; Taiki Higo; Takuya Nagata; Tetsuya Matoba; Toshiaki Kadokami; Yasuhiro Nakano; Yasushi Mukai; Yusuke Akiyama
Source
Journal of Atherosclerosis and Thrombosis. 2023, 30(8):907
Subject
Language
English
ISSN
1340-3478
1880-3873
1880-3873
Abstract
Results: After the treatment period, the S＋E group had significantly lower level of low-density lipoprotein cholesterol (LDL-C; 80.9±3.7 vs. 67.7±3.8 mg/dL, p=0.0143). Campesterol, a marker of cholesterol absorption, and oxysterols (β-epoxycholesterol, 4β-hydroxycholesterol, and 27-hydroxycholesterol) were also lower in the S＋E group. IVUS analyses revealed greater plaque regression in the S＋E group than in the S group (−6.14% vs. −1.18% for each group, p=0.042). It was noteworthy that the lowering of campesterol and 27-hydroxycholesterol, but not LDL-C, had a significant positive correlation with plaque regression.